Clonal Evolution of FLT3 -ITD Positive AML in Patients Treated with Midostaurin in Combination with Chemotherapy within the Ratify (CALGB 10603) and AMLSG 16-10 Trials

Laura K Schmalbrock ,Konstanze Döhner ,Richard A Larson ,Frauke Theis ,Hartmut Döhner ,Nikolaus Jahn ,Helmut R Salih ,Verena I Gaidzik ,Gerald Wulf ,Michael Lübbert ,Walter Fiedler ,Mridul Agrawal ,Felicitas Thol ,Michael Heuser ,Sibylle Cocciardi ,Richard Stone ,Arnold Ganser ,Richard F Schlenk ,Ulrich Germing ,Anna Dolnik ,Tamara J Blätte ,Ekaterina Panina ,Peter Paschka ,Lars Bullinger

doi:10.1182/blood.v130.suppl_1.182.182

Clonal Evolution of FLT3 -ITD Positive AML in Patients Treated with Midostaurin in Combination with Chemotherapy within the Ratify (CALGB 10603) and AMLSG 16-10 Trials

Laura K Schmalbrock , Konstanze Döhner + Show 22 more

https://doi.org/10.1182/blood.v130.suppl_1.182.182

Copy DOI

Export

Save

Cite

Journal: Blood

Publication Date: Jun 25, 2021

Affiliation: University Hospital Ulm, University of Chicago, University Children's Hospital Tübingen, Universitätsmedizin Göttingen, University Medical Center Freiburg, Eppendorf (Germany), Hannover Medical School, CancerCare, National Center for Tumor Diseases, Heinrich Heine University Düsseldorf

#Internal Tandem Duplications #Research Funding #RATIFY Trial #Advisory Committees #Entity's Board #Board Of Directors #Epigenetic Modifying Genes #Whole Exome Sequencing #Significant Proportion Of Pts #NPM1 Mut

Abstract
Full-Text
Similar Papers

Abstract

Listen

Clonal Evolution of FLT3 -ITD Positive AML in Patients Treated with Midostaurin in Combination with Chemotherapy within the Ratify (CALGB 10603) and AMLSG 16-10 Trials

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Clonal Evolution of FLT3 -ITD Positive AML in Patients Treated with Midostaurin in Combination with Chemotherapy within the Ratify (CALGB 10603) and AMLSG 16-10 Trials